分类： 新闻

伙伴关系的力量。瑞士和中国树立了榜样。

In this video, Professor Jean-Marc Burgunder, head of the Huntington’s Disease (HD) centre in Bern Switzerland, and Xi Cao, President of the Chinese HD Association talk about the benefits of […]

宜居生活》--一本重点介绍世界各地受 HD 影响的人们的故事的新书

PRESS RELEASE – October 25, 2024, Moscow, Idaho, USAWe are pleased to announce the launch of a new book about Huntington’s disease (HD) called, Livable Lives: Conversations with the Huntington’s […]

LoQus23 Therapeutics 公司宣布融资 3500 万英镑，用于开发一种抑制亨廷顿氏病体细胞扩增的新药

Cambridge, UK, 2 October 2024 – LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that could stop DNA instability and slow neurodegeneration in Huntington’s Disease, myotonic dystrophy […]

FDA 授予 PTC518 亨廷顿氏病项目快速通道称号

PTC518 is an oral medication that reduces the production of the mutated Huntingtin protein that causes disease progression.   Programs with Fast Track designation can benefit from early interactions with the FDA, and may be […]

Prilenia 公司治疗亨廷顿氏症的普利多匹定接受欧洲上市许可审查

Prilenia 是一家处于临床阶段的生物技术公司，致力于开发新型疗法以延缓神经退行性疾病和神经发育障碍的进展。

IROS、Prilenia 和国际亨廷顿氏病协会合作在中东和北非地区首次开展亨廷顿氏病 (HD) 试验

Abu Dhabi, UAE; June 19, 2024: IROS, an Abu Dhabi-based contract research organization (part of the M42 group), has partnered with Prilenia Therapeutics, a clinical-stage biotech company, and the International […]

uniQure 公布最新中期积极数据，显示 AMT-130 治疗 HD 的 I/II 期试验疾病进展放缓

“We are very pleased with these new data demonstrating a statistically significant, dose-dependent slowing of the progression of Huntington’s disease and lowering of NfL in the CSF at 24 months,” […]

Wave 生命科学公司宣布 SELECT-HD 1b/2a 期试验取得积极成果，首次在临床上证明可降低亨廷顿氏症患者的等位基因选择性突变亨廷廷蛋白水平

Today, Wave Life Sciences announced positive results from SELECT-HD, our Phase 1b/2a placebo-controlled trial evaluating the investigational therapy WVE-003. These results demonstrate that WVE-003 selectively lowers toxic, mutant huntingtin (mHTT) […]

PTC 今天宣布，其口服 PTC518 的 2 期 PIVOT-HD 研究在 12 个月内取得了令人鼓舞的结果  

At Month 12, mutant Huntingtin (mHTT) in the blood was lowered by 22% and 43% respectively for 5mg and 10mg doses. A similar result was seen in cerebrospinal fluid, where […]

Sage Therapeutics 公司的 2 期研究证实了亨廷顿氏症对认知的影响

Earlier this week Sage Therapeutics announced the results of their SURVEYOR study which quantified the cognitive impact of Huntington’s Disease.  Using the HD-Cognitive Assessment Battery (HD-CAB) they measured the difference […]